兰诺地近 | 33156-28-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 兰诺地近
• 英文名称: digitoxigenin‐α‐L‐amiceto‐pyranoside
• 英文别名: 3β-(2',3'-Didesoxy-α-L-rhamnopyranosyloxy)digitoxigenin；digitoxigenin 3-(α-L-amecitopyranoside)；Ramnodigin；3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-3-[(2R,5R,6S)-5-hydroxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
• CAS: 33156-28-4
• 化学式: C₂₉H₄₄O₆
• 分子量: 488.665
• InChiKey: LDZRENBZALBYIS-XZUAUHNRSA-N

物化性质

• 熔点：
  172-173 °C
• 沸点：
  646.6±55.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  35
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  tert-butyl ((2S,6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl) carbonate 在 N-甲基吗啉 、 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 sodium tetrahydroborate 、 cerium(III) chloride 、 2-硝基苯磺酰肼 、 三乙胺 、 三苯基膦 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 36.0h， 生成 兰诺地近
  参考文献：
  名称：

  α-d-/α-l-鼠李糖基和氨乙酰洋地黄毒苷低聚物作为抗肿瘤剂的合成和评价

  摘要：

  通过钯催化的糖基化，然后是双-/三-二羟基化或双-/三-二亚胺还原，已经建立了鼠李糖基-和氨乙酰-洋地黄毒苷类似物的高度区域和立体选择性不对称合成。α- l-鼠李糖和 α- l-鼠李糖单糖类似物对非小细胞人肺癌细胞 (NCI-H460) 显示出更强的凋亡诱导活性和细胞毒性，比其d-非对映异构体以糖链长度依赖性方式。

  DOI：

  10.1021/ml100290d

文献信息

• Synthesis and Evaluation of the α-<scp>d</scp>-/α-<scp>l</scp>-Rhamnosyl and Amicetosyl Digitoxigenin Oligomers as Antitumor Agents
  作者：Hua-Yu Leo Wang、Yon Rojanasakul、George A. O’Doherty

  DOI：10.1021/ml100290d

  日期：2011.4.14

  A highly regio- and stereoselective asymmetric synthesis of rhamnosyl- and amicetosyl-digitoxigenin analogues has been established via palladium-catalyzed glycosylation followed by bis-/tris-dihydroxylation or bis-/tris-diimide reduction. The α-l-rhamnose and α-l-amicetose digitoxin monosaccharide analogues displayed stronger apoptosis inducing activity and cytotoxicity against nonsmall cell human

  通过钯催化的糖基化，然后是双-/三-二羟基化或双-/三-二亚胺还原，已经建立了鼠李糖基-和氨乙酰-洋地黄毒苷类似物的高度区域和立体选择性不对称合成。α- l-鼠李糖和 α- l-鼠李糖单糖类似物对非小细胞人肺癌细胞 (NCI-H460) 显示出更强的凋亡诱导活性和细胞毒性，比其d-非对映异构体以糖链长度依赖性方式。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• C5′-Alkyl Substitution Effects on Digitoxigenin α-<scp>l</scp>-Glycoside Cancer Cytotoxicity
  作者：Hua-Yu Leo Wang、Bulan Wu、Qi Zhang、Sang-Woo Kang、Yon Rojanasakul、George A. O’Doherty

  DOI：10.1021/ml100291n

  日期：2011.4.14

  A highly regio- and stereoselective asymmetric synthesis of various CS'-alkyl side chains of rhamnosyl- and amicetosyl-digitoxigenin analogues has been established via palladium-catalyzed glycosylation with postglycosylated dihydroxylation or diimide reduction. The C5'-methyl group in both alpha-L-rhamnose and cc-L-amicetose digitoxin analogues displayed a steric directed apoptosis induction and tumor growth inhibition against nonsmall cell human lung cancer cells (NCI-H460). The antitumor activity is significantly reduced when the steric hindrance is increased at the C5'-stereocenter.
• Stache, Ulrich; Radscheit, Kurt; Haede, Werner, Angewandte Chemie, 1982, vol. 94, # 7, p. 560 - 561
  作者：Stache, Ulrich、Radscheit, Kurt、Haede, Werner、Fritsch, Werner

  DOI：——

  日期：——